{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:15:05Z","timestamp":1790957705326,"version":"4.1.0"},"reference-count":31,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014926","name":"Acceleron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014926","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,8,2]]},"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo. This report characterises the longer-term safety and efficacy of sotatercept in the PULSAR open-label extension. We report cumulative safety, and efficacy at months 18\u201324, for all participants treated with sotatercept.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PULSAR was a phase 2, randomised, double-blind, placebo-controlled study followed by an open-label extension, which evaluated sotatercept on top of background pulmonary arterial hypertension therapy in adults. Participants originally randomised to placebo were re-randomised 1:1 to sotatercept 0.3 or 0.7\u2005mg\u00b7kg<jats:sup>\u22121<\/jats:sup>(placebo-crossed group); those initially randomised to sotatercept continued the same sotatercept dose (continued-sotatercept group). Safety was evaluated in all participants who received \u22651 dose of sotatercept. The primary efficacy endpoint was change from baseline to months 18\u201324 in pulmonary vascular resistance. Secondary endpoints included 6-min walk distance and functional class. Two prespecified analyses, placebo-crossed and delayed-start, evaluated efficacy irrespective of dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 106 participants enrolled in the PULSAR study, 97 continued into the extension period. Serious treatment-emergent adverse events were reported in 32 (30.8%) participants; 10 (9.6%) reported treatment-emergent adverse events leading to study discontinuation. Three (2.9%) participants died, none considered related to study drug. The placebo-crossed group demonstrated significant improvement across primary and secondary endpoints and clinical efficacy was maintained in the continued-sotatercept group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results support the longer-term safety and durability of clinical benefit of sotatercept for pulmonary arterial hypertension.<\/jats:p><\/jats:sec>","DOI":"10.1183\/13993003.01347-2022","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T10:05:10Z","timestamp":1661853910000},"page":"2201347","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":150,"title":["Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension"],"prefix":"10.1183","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2892","authenticated-orcid":false,"given":"Marc","family":"Humbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallerie","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Simon R.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mardi","family":"Gomberg-Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9086-2293","authenticated-orcid":false,"given":"Marius M.","family":"Hoeper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana R.","family":"Preston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2789-9143","authenticated-orcid":false,"given":"Rogerio","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7797-0361","authenticated-orcid":false,"given":"Aaron B.","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2029-4419","authenticated-orcid":false,"given":"Hossein-Ardeschir","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6640-4839","authenticated-orcid":false,"given":"Pilar","family":"Escribano Subias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-6922","authenticated-orcid":false,"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solaiappan","family":"Manimaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janethe","family":"de Oliveira Pena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Badesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"2024102103041098000_61.1.2201347.1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"key":"2024102103041098000_61.1.2201347.2","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.drudis.2018.12.001","article-title":"TGF\u03b2 and BMPRII signalling pathways in the pathogenesis of pulmonary arterial hypertension","volume":"24","author":"Tielemans","year":"2019","journal-title":"Drug Discov Today"},{"key":"2024102103041098000_61.1.2201347.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01899-2018"},{"key":"2024102103041098000_61.1.2201347.4","doi-asserted-by":"crossref","first-page":"eeaz5660","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci Transl Med"},{"key":"2024102103041098000_61.1.2201347.5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.31083\/j.rcm.2020.02.597","article-title":"Current and emerging therapeutic approaches to pulmonary hypertension","volume":"21","author":"Bisserier","year":"2020","journal-title":"Rev Cardiovasc Med"},{"key":"2024102103041098000_61.1.2201347.6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12170-020-00663-3","article-title":"Management of pulmonary arterial hypertension","volume":"15","author":"Mayeux","year":"2021","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"2024102103041098000_61.1.2201347.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01889-2018"},{"key":"2024102103041098000_61.1.2201347.8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv317"},{"key":"2024102103041098000_61.1.2201347.9","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1460"},{"key":"2024102103041098000_61.1.2201347.10","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000029100.82385.58"},{"key":"2024102103041098000_61.1.2201347.11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/MCP.0000000000000404","article-title":"New targets for pulmonary arterial hypertension: going beyond the currently targeted three pathways","volume":"23","author":"Huertas","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"2024102103041098000_61.1.2201347.12","first-page":"A3657","article-title":"Sotatercept analog RAP-011 alleviates cardiopulmonary remodeling and inflammation in a model of heritable PAH arising from BMPR2 haploinsufficiency","volume":"203","author":"Joshi","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103041098000_61.1.2201347.13","first-page":"16179","article-title":"RAP-011, a murine ortholog of ActRIIA-FC (sotatercept), improves pulmonary hemodynamics and restores right ventricular structure and function in a preclinical model of severe angio-obliterative pulmonary arterial hypertension","volume":"138","author":"Joshi","year":"2018","journal-title":"Circulation"},{"key":"2024102103041098000_61.1.2201347.14","unstructured":"ClinicalTrials.gov . A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (SPECTRA). Date last accessed: 16 December 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03738150"},{"key":"2024102103041098000_61.1.2201347.15","unstructured":"ClinicalTrials.gov . A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (STELLAR). Date last accessed: 22 November 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04576988"},{"key":"2024102103041098000_61.1.2201347.16","unstructured":"ClinicalTrials.gov . Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk PAH Patients (HYPERION). Date last accessed: 22 November 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04811092"},{"key":"2024102103041098000_61.1.2201347.17","unstructured":"ClinicalTrials.gov . A Study of Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality (ZENITH). Date last accessed: 22 November 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04896008"},{"key":"2024102103041098000_61.1.2201347.18","unstructured":"ClinicalTrials.gov . A Long-term Follow-up Study of Sotatercept for PAH Treatment (SOTERIA). Date last accessed: 22 November 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04796337"},{"key":"2024102103041098000_61.1.2201347.19","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/10543406.2019.1696355","article-title":"Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures","volume":"30","author":"Ouyang","year":"2020","journal-title":"J Biopharm Stat"},{"key":"2024102103041098000_61.1.2201347.20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1164\/rccm.201801-0081PP","article-title":"Hematocrit-corrected pulmonary vascular resistance","volume":"198","author":"Vanderpool","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103041098000_61.1.2201347.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.05.025"},{"key":"2024102103041098000_61.1.2201347.22","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(16)30019-4","article-title":"Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial","volume":"4","author":"Ghofrani","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102103041098000_61.1.2201347.23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s12325-021-01898-1","article-title":"Long-term survival, safety and tolerability with selexipag in patients with pulmonary arterial hypertension: results from GRIPHON and its open-label extension","volume":"39","author":"Galie","year":"2022","journal-title":"Adv Ther"},{"key":"2024102103041098000_61.1.2201347.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209655"},{"key":"2024102103041098000_61.1.2201347.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"2024102103041098000_61.1.2201347.26","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12835"},{"key":"2024102103041098000_61.1.2201347.27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.198887"},{"key":"2024102103041098000_61.1.2201347.28","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00520-015-2929-9","article-title":"Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies","volume":"24","author":"Raftopoulos","year":"2016","journal-title":"Support Care Cancer"},{"key":"2024102103041098000_61.1.2201347.29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc2107209","article-title":"Sotatercept for pulmonary arterial hypertension","volume":"385","author":"Yang","year":"2021","journal-title":"N Engl J Med"},{"key":"2024102103041098000_61.1.2201347.30","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/S2352-3026(18)30002-4","article-title":"Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial","volume":"5","author":"Komrokji","year":"2018","journal-title":"Lancet Haematol"},{"key":"2024102103041098000_61.1.2201347.31","first-page":"A1187","article-title":"The SPECTRA study: a phase 2a single-arm, open-label, multicenter exploratory study to assess the effects of sotatercept for the treatment of pulmonary arterial hypertension (PAH)","volume":"203","author":"Waxman","year":"2021","journal-title":"Am J Respir Crit Care Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01347-2022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:08:50Z","timestamp":1740380930000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01347-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,6]]},"published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.1183\/13993003.01347-2022"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01347-2022","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}